Pharma and Biotech
| Final Results | 29-Apr-2026 | 07:00 | RNS |
| Granted U.S. Patent from PTSD Discovery Programme | 08-Apr-2026 | 07:00 | RNS |
| Granted U.S. Patent from PTSD Discovery Programme | 31-Mar-2026 | 07:00 | RNS |
| SVN-114 selected for PTSD discovery programme | 10-Mar-2026 | 07:00 | RNS |
| SVN-114 selected for PTSD discovery programme | 10-Mar-2026 | 07:00 | RNS |
| Expansion of SVN-015 into depression | 28-Jan-2026 | 07:00 | RNS |
| US Patent allowance for PTSD discovery programme | 07-Jan-2026 | 07:00 | RNS |
| Research and Development Update – Q4 2025 | 22-Dec-2025 | 07:00 | RNS |
| Research and Development Update – Q4 2025 | 22-Dec-2025 | 07:00 | RNS |
| SVN-015 accepted into US NIDA funded programme | 03-Dec-2025 | 07:00 | RNS |
| Appoints global biopharma leader Paul Carter | 27-Oct-2025 | 07:00 | RNS |
| Raises £1.25 Million to Accelerate Programmes | 16-Oct-2025 | 07:00 | RNS |
| Half-year Report | 30-Sep-2025 | 07:00 | RNS |
| Solvonis secures exclusive CNS collaboration | 28-Aug-2025 | 07:00 | RNS |
| SVN-SDN-14 PTSD - Positive pre-clinical results | 12-Aug-2025 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 0.24p |
| Change Today | 0.010p |
| % Change | 4.35 % |
| 52 Week High | 0.25 |
| 52 Week Low | 0.23 |
| Volume | 32,967,323 |
| Shares Issued | 6,806m |
| Market Cap | £16.34m |
| Beta | 0.02 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:19 | 1,000,000 @ 0.24p |
| 14:06 | 414,281 @ 0.24p |
| 14:01 | 19,168 @ 0.24p |
| 14:00 | 4,871,530 @ 0.23p |
| 14:00 | 871,530 @ 0.23p |
| CEO | Anthony Tennyson |
| Chair | Dennis Purcell |
You are here: research